ECE2013 Poster Presentations Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (127 abstracts)
Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study
Pamela Freda 1 , Maria Fleseriu 2 , Aart Jan van der Lely 3 , Annamaria Colao 4 , Michael Sheppard 5 , Feng Gu 6 , Chiung-Chyi Shen 7, , Monica Gadelha 9 , Andrew Farrall 10 , Karina Hermosillo Reséndiz 11 , Matthieu Ruffin 12 , YinMiao Chen 11 & Marcello Bronstein 13
1Columbia University College of Physicians & Surgeons, New York, New York, USA; 2Oregon Health & Science University, Portland, Oregon, USA; 3Erasmus University Medical Centre, Rotterdam, The Netherlands; 4Università Federico II di Napoli, Naples, Italy; 5University of Birmingham, Edgbaston, Birmingham, UK; 6Peking Union Medical College Hospital, Beijing, China; 7Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan; 8Hungkuang University, Taichung, Taiwan; 9Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 10University of Edinburgh, Edinburgh, UK; 11Novartis Pharmaceuticals Corporation, Florham Park, New Jersey, USA; 12Novartis Pharma AG, Basel, Switzerland; 13University of São Paolo Medical School, São Paolo, Brazil.
Introduction: In a Phase III trial, pasireotide LAR was significantly superior (P=0.007) to octreotide LAR at providing biochemical control at 12 months in medically naïve acromegaly patients (post-pituitary surgery or de novo). Inadequately controlled patients (GH≥2.5 μg/l and/or IGF-1>ULN) at the end of core study were eligible for switching therapy (crossover extension). Reported here are efficacy results up to 12 months and safety results up to 13 months post-crossover.
Methods: Eligible patients were switched to either pasireotide LAR 40 mg/28 days (n=81) or octreotide LAR 20 mg/28 days (n=38). One dose escalation to pasireotide LAR 60 mg/28 days or octreotide LAR 30 mg/28 days was permitted, but not mandatory, post-crossover. Main outcome measures included GH<2.5 μg/l and normal IGF-1 12 months after switching medical therapy.
Results: A 31 pasireotide LAR and 13 octreotide LAR patients discontinued within 12 months after crossover. Response rates (95% CI) 12 months after crossover to pasireotide LAR (n=81) and octreotide LAR (n=38), respectively: GH<2.5 μg/l and normal IGF-1, 17.3% (9.8–27.3) and 0%; normal IGF-1, 27.2% (17.9–38.2) and 5.3% (0.6–17.7); GH<2.5 μg/l, 44.4% (33.4–55.9) and 23.7% (11.4–40.2); tumor volume decreased from extension baseline by a mean (SD) of 24.7% (25.2) and 17.9% (27.8). A significant (≥20%) tumor volume reduction from extension baseline was seen in 54.3% (25/46) of pasireotide LAR and 42.3% (11/26) of octreotide LAR patients. Safety profile of both agents was consistent with that seen in the core trial and with somatostatin analogues. Hyperglycemia-related AEs, while mostly mild or moderate, were more frequent with pasireotide LAR (64.2%) than octreotide LAR (21.1%). Fasting plasma glucose and HbA1c levels decreased to near normal levels within 3 months after switching from pasireotide LAR to octreotide LAR.
Conclusions: Pasireotide LAR holds promise as a treatment option for acromegaly patients inadequately controlled with octreotide LAR. Hyperglycemia associated with pasireotide LAR appeared to be reversible upon discontinuation of pasireotide.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more